Ross Marchand

4 days ago | wvgazettemail.com | Ross Marchand

The Trump administration is laudably committed to rooting out waste across the federal government and axing large and ineffective programs. There are some early encouraging signs that the Food and Drug Administration will reduce spending and needless red tape in line with the administration’s government-wide push. For example, FDA Commissioner Marty Makary has pledged to create an expedited pathway for approving therapies for rare diseases and to use artificial intelligence to expedite approvals.

5 days ago | issuesinsights.com | Ross Marchand

People are accustomed to long and unnecessary doctor’s visits to receive a diagnosis and then have a prescription given to them. The process is tedious, costly, and in some cases, unnecessary. That old dynamic may be changing, as many come to realize the absurdity of locking away therapies behind the counter. Recently, health care and biotech writer Alex Kesin wrote to Department of Health and Human Services Secretary Robert F.

1 week ago | grandforksherald.com | Ross Marchand

The Trump administration is laudably committed to rooting out waste across the federal government and axing large and ineffective programs. There are some early encouraging signs that the Food and Drug Administration will reduce spending and needless red tape in line with the administration’s government-wide push.

1 week ago | latrobebulletinnews.com | Ross Marchand

The Trump administration is laudably committed to rooting out waste across the federal government and axing large and ineffective programs. There are some early encouraging signs that the Food and Drug Administration will reduce spending and needless red tape in line with the administration’s government-wide push. For example, FDA Commissioner Marty Makary has pledged to create an expedited pathway for approving therapies for rare diseases and to use artificial intelligence to expedite approvals.

1 week ago | bostonherald.com | Ross Marchand

The Trump administration is laudably committed to rooting out waste across the federal government and axing large and ineffective programs. There are some early encouraging signs that the Food and Drug Administration will reduce spending and needless red tape in line with the administration’s government-wide push. For example, FDA Commissioner Marty Makary has pledged to create an expedited pathway for approving therapies for rare diseases and to use artificial intelligence to expedite approvals.